Role of complement activation in atherosclerosis

Purpose of review Atherosclerosis is characterized by a strong inflammatory component. One factor contributing to inflammation in the arterial intima is the complement system. Here we summarize recent progress in the field of complement research on atherogenesis. Recent findings The complement system is activated in human atherosclerotic lesions and is actively regulated by the local synthesis of complement components and of complement regulatory proteins. Potential triggers of complement activation in the arterial intima include immunocomplexes, C-reactive protein, modified lipoproteins, apoptotic cells, and cholesterol crystals. Complement activation releases anaphylatoxins, and anaphylatoxin receptors have been identified in human atherosclerotic lesions. However, experiments on genetically engineered mice with severe hyperlipidemia have been unable to show a major role for complement in experimental atherogenesis. Summary In humans there is extensive circumstantial evidence for a role of complement in atherosclerosis, which is somewhat contradictory to recent modest or negative findings in atherosclerosis-prone genetically engineered hyperlipidemic mice.

[1]  S. Meri,et al.  Association Between Complement Factor H and Proteoglycans in Early Human Coronary Atherosclerotic Lesions: Implications for Local Regulation of Complement Activation , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[2]  R. Schmidt,et al.  C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. , 2002, The Journal of clinical investigation.

[3]  S. Meri,et al.  Binding of C-reactive protein to modified low-density-lipoprotein particles: identification of cholesterol as a novel ligand for C-reactive protein. , 2002, The Biochemical journal.

[4]  Janet M. Allen,et al.  C‐reactive protein‐mediated phagocytosis and phospholipase D signalling through the high‐affinity receptor for immunoglobulin G (FcγRI) , 2002 .

[5]  J. Witztum,et al.  C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Meri,et al.  Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. , 2002, The American journal of cardiology.

[7]  C. Come,et al.  Influence of C3 Deficiency on Atherosclerosis , 2002, Circulation.

[8]  C. Garlanda,et al.  Production of the Long Pentraxin PTX3 in Advanced Atherosclerotic Plaques , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Ralph Weissleder,et al.  Arthritis critically dependent on innate immune system players. , 2002, Immunity.

[10]  Janet M. Allen,et al.  C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcgammaRI). , 2002, Immunology.

[11]  Y. Chao,et al.  ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5. , 2001, Biochemical and biophysical research communications.

[12]  T. Kodama,et al.  CD11b/CD18 Mediates Production of Reactive Oxygen Species by Mouse and Human Macrophages Adherent to Matrixes Containing Oxidized LDL , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[13]  J. Köhl,et al.  Distinct Tissue Site-Specific Requirements of Mast Cells and Complement Components C3/C5a Receptor in IgG Immune Complex-Induced Injury of Skin and Lung1 , 2001, The Journal of Immunology.

[14]  P. Mcgeer,et al.  Complement Components, but Not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[15]  P. Mcgeer,et al.  Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.

[16]  H. Rus,et al.  Mechanism of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells , 2001, Immunologic research.

[17]  S. Meri,et al.  Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. , 1999, Journal of immunology.

[18]  S. Bhakdi,et al.  Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[19]  H. Rus,et al.  Complement activation and atherosclerosis. , 1999, Molecular immunology.

[20]  N. Davoust,et al.  Human T cells express the C5a receptor and are chemoattracted to C5a. , 1999, Journal of immunology.

[21]  A. Aderem,et al.  Mechanisms of phagocytosis in macrophages. , 1999, Annual review of immunology.

[22]  T. Badea,et al.  Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. , 1999, Atherosclerosis.

[23]  D. Mevorach,et al.  Complement-dependent Clearance of Apoptotic Cells by Human Macrophages , 1998, The Journal of experimental medicine.

[24]  R. Kinscherf,et al.  Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[25]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[26]  R. Tompkins,et al.  Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. , 1998, The Journal of infectious diseases.

[27]  H. Gabbert,et al.  Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[28]  V. Hombach,et al.  Immunohistochemical colocalization of the terminal complex of human complement and smooth muscle cell alpha-actin in early atherosclerotic lesions. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[29]  P. Ward,et al.  Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. , 1997, The American journal of pathology.

[30]  A. Mantovani,et al.  The Cytolytically Inactive Terminal Complement Complex Activates Endothelial Cells to Express Adhesion Molecules and Tissue Factor Procoagulant Activity , 1997, The Journal of experimental medicine.

[31]  C. Dinarello,et al.  A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. , 1996, Journal of immunology.

[32]  P. Lachmann,et al.  Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[33]  S. Bhakdi,et al.  On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety , 1995, The Journal of experimental medicine.

[34]  P. Ward,et al.  Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. , 1995, Journal of immunology.

[35]  P. Ward,et al.  C5a-induced expression of P-selectin in endothelial cells. , 1994, The Journal of clinical investigation.

[36]  J. Halperin,et al.  Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells , 1994, The Journal of experimental medicine.

[37]  H. Rus,et al.  Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes. , 1994, The Journal of biological chemistry.

[38]  D. Steinberg,et al.  Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[39]  T. Imamichi,et al.  Characterization of C3a anaphylatoxin receptor on guinea-pig macrophages. , 1993, Immunology.

[40]  I. Roth,et al.  CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. , 1992, Atherosclerosis.

[41]  T. Ueno,et al.  Complement receptors in atherosclerotic lesions. , 1992, Artery.

[42]  S. Bhakdi,et al.  Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions , 1990, The Journal of experimental medicine.

[43]  G. Hansson,et al.  Complement receptors and regulatory proteins in human atherosclerotic lesions. , 1989, Arteriosclerosis.

[44]  H. Rus,et al.  Immunoelectron-microscopic localization of S-protein/vitronectin in human atherosclerotic wall. , 1989, Atherosclerosis.

[45]  G. Hansson,et al.  Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[46]  P. Sims,et al.  Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. , 1989, The Journal of biological chemistry.

[47]  W. Arend,et al.  Absence of induction of IL-1 production in human monocytes by complement fragments. , 1989, Journal of immunology.

[48]  C. Dinarello,et al.  C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha , 1988, The Journal of experimental medicine.

[49]  P. Henson,et al.  Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. , 1988, The Journal of clinical investigation.

[50]  M. Kazatchkine,et al.  Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. , 1987, Molecular immunology.

[51]  H. Rus,et al.  Activation of the human terminal complement pathway in atherosclerosis. , 1987, Clinical immunology and immunopathology.

[52]  Reynolds Gd,et al.  C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. , 1987 .

[53]  R. Vance,et al.  C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. , 1987, Archives of pathology & laboratory medicine.

[54]  W. Seeger,et al.  Noncytolytic terminal complement complexes may serve as calcium gates to elicit leukotriene B4 generation in human polymorphonuclear leukocytes. , 1986, Journal of immunology.

[55]  H. Rus,et al.  Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. , 1986, Atherosclerosis.

[56]  H. Rus,et al.  Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. , 1985, Atherosclerosis.

[57]  H. Rus,et al.  Quantitative determinations of immunoglobulins and complement components in human aortic atherosclerotic wall. , 1985, Medecine interne.

[58]  M. Thoman,et al.  Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. , 1983, Journal of immunology.

[59]  A. Feinstein,et al.  Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein , 1982, The Journal of experimental medicine.

[60]  S. Bhakdi,et al.  Fluid-phase SC5b-8 complex of human complement: generation and isolation from serum. , 1981, Journal of immunology.

[61]  H. Jacob,et al.  Cholesterol and atheroma lipids activate complement and stimulate granulocytes. A possible mechanism for amplification of ischemic injury in atherosclerotic states. , 1981, The Journal of laboratory and clinical medicine.

[62]  P. Henson,et al.  Induction of lysosomal enzyme secretion by alveolar macrophages in response to the purified complement fragments C5a and C5a des-arg. , 1979, Journal of immunology.

[63]  H. Sørensen,et al.  Complement as a factor in arteriosclerosis. , 1970, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.